MyoTherix, Inc. is a clinical stage, biopharmaceutical company focused on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments.
Research focus: Anti-inflammatory and anti-osteoporosis. MyoTherix’s lead clinical research program focusses on targeting the P2X7 pathway to improve muscle function and bone health and potentially reduce the side-effects from steroid use. The MyoTherix pre-clinical research program focusses on improving both cardiac and skeletal muscle function, reducing inflammation, and facilitating new muscle regeneration.
Status: Clinical and Preclinical Research Projects
“MyoTherix’s lead research program intends to improve both cardiac and skeletal muscle function, as well as reduce inflammation and facilitate new muscle regeneration. We are pleased to work with the team at CureDuchenne and look forward to developing this new approach to the treatment of this devastating disease.” — John Kincaid, co-Founder of MyoTherix Inc.